Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dipyrocetyl is a small molecule pharmaceutical drug classified as an acylsalicylic acid derivative and member of the salicylates. It is used as an analgesic and antipyretic agent. Dipyrocetyl has also demonstrated potential anticoagulant properties and may inhibit matrix metalloproteinase-2 (MMP2). There is evidence suggesting it could be useful in treating acute lung injury (ALI) associated with acute respiratory distress syndrome (ARDS), possibly by improving tissue integrity and reducing pro-inflammatory cytokine activation. Its primary mechanism of action appears to involve inhibition of prostaglandin synthesis via cyclooxygenase (COX) enzyme inhibition[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dipyrocetyl.